A Survey of the Management of Diabetic Macular Oedema in Sub-Saharan Africa

Overview

Journal Niger Med J

Specialty General Medicine

Date 2024 Jun 18

PMID 38887433

Authors

Adetunji Olusesan Adenekan

Evelyn Mensah

Kwesi Nyan Amissah-Arthur

Affiliations

Soon will be listed here.

Abstract

Background: There is minimal information about the availability of treatment for Diabetic macular oedema (DMO) in sub-Saharan Africa (SSA). The principal aim of this survey was to determine the 'real world' management of DMO amongst ophthalmologists working in SSA.

Methodology: Questionnaires were distributed to members of retinal and ophthalmological societies in SSA.

Results: Ninety-Three ophthalmologists from 24 countries participated with the majority working in Nigeria (51, 55%). Most were retina specialists (50, 54%) and consultants (67, 62%). Clinically significant macular oedema prompted treatment for 62 (67%) ophthalmologists, whilst visual acuity (81, 87%) and OCT changes (76, 82%) were more common reasons to treat DMO. Treatment included intravitreal anti-VEGF (91, 98%), laser (70, 75%), intravitreal steroid (57, 61%), topical drops (52, 56%), oral tablets (32, 34%) and surgery (20, 22%). The commonest intravitreal anti-VEGF agents used were bevacizumab (89, 96%) and ranibizumab (71, 76%). Intravitreal triamcinolone was used by 69 (74%), topical NSAIDs by 51 (55%), and acetazolamide tablets by 22 (24%) ophthalmologists as a treatment for DMO.

Conclusion: Sub-Saharan African ophthalmologists commonly use intravitreal anti-VEGF, laser, intravitreal steroid, and topical NSAIDs to treat DMO. Economic constraints and/or the inability to maintain the intensive regimen required for successful intravitreal anti-VEGF therapy probably influence some treatment choices.

References

Lachin J, Genuth S, Cleary P, Davis M, Nathan D . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6):381-9. PMC: 2630213. DOI: 10.1056/NEJM200002103420603. View

Mathenge W, Bastawrous A, Peto T, Leung I, Yorston D, Foster A . Prevalence and correlates of diabetic retinopathy in a population-based survey of older people in Nakuru, Kenya. Ophthalmic Epidemiol. 2014; 21(3):169-77. DOI: 10.3109/09286586.2014.903982. View

Kelkar A, Webers C, Shetty R, Kelkar J, Labhsetwar N, Pandit A . Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in Indian patients with retinal vein occlusion, age-related macular degeneration, and diabetic macular edema. Indian J Ophthalmol. 2020; 68(10):2143-2147. PMC: 7728040. DOI: 10.4103/ijo.IJO_1866_19. View

Zhang X, Saaddine J, Chou C, Cotch M, Cheng Y, Geiss L . Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010; 304(6):649-56. PMC: 2945293. DOI: 10.1001/jama.2010.1111. View

Das T, Aurora A, Chhablani J, Giridhar A, Kumar A, Raman R . Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines. Indian J Ophthalmol. 2016; 64(1):14-25. PMC: 4821115. DOI: 10.4103/0301-4738.178142. View

Lee R, Wong T, Sabanayagam C . Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015; 2:17. PMC: 4657234. DOI: 10.1186/s40662-015-0026-2. View

Tsegaw A, Alemu S, Dessie A, Patterson C, Parry E, Phillips D . Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients Attending the Diabetic Clinic of the University of Gondar Hospital, Northwest Ethiopia. J Ophthalmol. 2021; 2021:6696548. PMC: 8026311. DOI: 10.1155/2021/6696548. View

Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A . IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138:271-281. DOI: 10.1016/j.diabres.2018.02.023. View

Thomas R, Dunstan F, Luzio S, Roy Chowdhury S, North R, Hale S . Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br J Ophthalmol. 2014; 99(1):64-8. DOI: 10.1136/bjophthalmol-2013-304017. View

10.

Vetrini D, Kiire C, Burgess P, Harding S, Kayange P, Kalua K . Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi. PLoS One. 2018; 13(1):e0190742. PMC: 5754125. DOI: 10.1371/journal.pone.0190742. View

11.

Raman R, Rani P, Kulothungan V, Rachepalle S, Kumaramanickavel G, Sharma T . Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology. 2010; 117(4):766-72. DOI: 10.1016/j.ophtha.2009.09.005. View

12.

Yau J, Rogers S, Kawasaki R, Lamoureux E, Kowalski J, Bek T . Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35(3):556-64. PMC: 3322721. DOI: 10.2337/dc11-1909. View

13.

Amoaku W, Ghanchi F, Bailey C, Banerjee S, Banerjee S, Downey L . Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020; 34(Suppl 1):1-51. PMC: 7337227. DOI: 10.1038/s41433-020-0961-6. View

14.

Amissah-Arthur K . Challenges with starting vitreoretinal services in the developing world. Nepal J Ophthalmol. 2017; 8(15):1-2. DOI: 10.3126/nepjoph.v8i1.16160. View

15.

Klein R, Klein B, Moss S, Cruickshanks K . The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998; 105(10):1801-15. DOI: 10.1016/S0161-6420(98)91020-X. View

16.

Bertelsen G, Peto T, Lindekleiv H, Schirmer H, Solbu M, Toft I . Tromsø eye study: prevalence and risk factors of diabetic retinopathy. Acta Ophthalmol. 2012; 91(8):716-21. DOI: 10.1111/j.1755-3768.2012.02542.x. View

17.

Klein R, Knudtson M, Lee K, Gangnon R, Klein B . The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009; 116(3):497-503. PMC: 2693093. DOI: 10.1016/j.ophtha.2008.10.016. View

18.

Lin S, Ramulu P, Lamoureux E, Sabanayagam C . Addressing risk factors, screening, and preventative treatment for diabetic retinopathy in developing countries: a review. Clin Exp Ophthalmol. 2016; 44(4):300-20. DOI: 10.1111/ceo.12745. View

19.

Klein R, Klein B, Moss S, Cruickshanks K . The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995; 102(1):7-16. DOI: 10.1016/s0161-6420(95)31052-4. View

20.

. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):703-13. PMC: 28659. View